Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
Journal of Virology|April 2, 2010
Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigenDavid M Iser, Nadia Warner, Peter A Revill, et al.Immunology and Cell Biology|November 1, 2020
Viperin binds STING and enhances the type-I interferon response following dsDNA detectionKeaton M Crosse, Ebony A Monson, Arti B Dumbrepatil, et al.Journal of Medical Virology|June 20, 2012
In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infectionLiza M Cabuang, Tim Shaw, Margaret Littlejohn, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virusGail V Matthews, Eric C Seaberg, Anchalee Avihingsanon, et al.Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.Hepatology (Baltimore, Md.)|June 24, 2008
Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceScott Preiss, Margaret Littlejohn, Peter Angus, et al.Plos Pathogens|September 8, 2020
Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infectionKasha P Singh, Jennifer M Zerbato, Wei Zhao, et al.Virology|July 27, 2010
HBV mutations in untreated HIV-HBV co-infection using genomic length sequencingJennifer Audsley, Margaret Littlejohn, Lilly Yuen, et al.Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.Journal of Hepatology|May 30, 2024
CRISPR-Cas13b-mediated suppression of HBV replication and protein expressionLaura C McCoullough, Mohamed Fareh, Wenxin Hu, et al.Pageof 6